Last reviewed · How we verify
NCT07065968
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Phase 2 trial testing Teriflunomide in Immune Thrombocytopenia (ITP) in 132 participants. Currently enrolling.
10 September 2027
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 132 |
| Start date | 19 August 2025 |
| Primary completion | 10 September 2027 |
| Estimated completion | 30 December 2027 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Teriflunomide (TERIFLUNOMIDE) — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Immune Thrombocytopenia (ITP) — all drugs for Immune Thrombocytopenia (ITP) →
Sponsor
Peking University People's Hospital
Who can join
18 and older, any sex, with Immune Thrombocytopenia (ITP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07065968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Teriflunomide
Trials testing the same drug.
- NCT06372145 — A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. · Phase 3 · active not recruiting
- NCT06176235 — Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia · Phase 2 · withdrawn
- NCT06141473 — Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis · Phase 3 · recruiting
- NCT06190145 — Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia · Phase 2 · unknown
- NCT06176911 — The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia · Phase 2 · unknown
Other recruiting trials for Immune Thrombocytopenia (ITP)
Currently open trials in the same condition.
- NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
- NCT07095127 — Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia · Phase 2 · recruiting
- NCT06973356 — Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia · NA · recruiting
- NCT06962631 — V-IMMUNE® for Immune Thrombocytopenia · Phase 3 · recruiting
- NCT06853444 — A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia · Phase 1, PHASE2 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07065968 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing